Future prospects for the staging of breast cancer

Seminars in Surgical Oncology

Volumn 12, Issue 1, 1996, Pages 3-11

  Rutgers, Emiel J Th ^a   Peterse, Hans L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

breast cancer; locoregional treatment; predictive factors; prognostic factors; staging; systemic adjuvant treatment

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; TAMOXIFEN; TUMOR ANTIGEN;

BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; HUMAN; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECOND CANCER; STANDARDIZATION; TREATMENT PLANNING;

EID: 0030041249     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199601/02)12:1<3::AID-SSU2>3.3.CO;2-B     Document Type: Review

References (61)

1. Varmus H, Weinberg RA: "Genes and the biology of Cancer." New York: Scientific American Library, 1993.
2. Oza AM, Tannock IF: Clinical relevance of breast cancer biology. Hematol Oncol Clin North Am 8:1-14, 1994.
3. Hermanek P, Sobin LH (eds): "TNM Classification of Malignant Tumours." 4th Ed. Berlin: Springer-Verlag, 1987.
4. Barr LC, Baum M: Time to abandon TNM staging of breast cancer. Lancet 339:915-17, 1992.
5. Yarnold J, Dixon JM, Greco M, on behalf of the European Society of Mastology: Consensus document on staging for breast cancer. Breast 3:238-240, 1994.
6. Nachlas MM: Irrationality in the management of breast cancer. I. The staging system. Cancer 68:681-90, 1991.
7. Holland R, Hendriks JHCL, Verbeek ALM et al.: Extent, distribution and mammographic histologic correlations of breast ductal carcinoma in situ. Lancet 335:514-522, 1990.
8. Faverly DRG, Burger L, Bult P, Holland R: Three dimensional imaging of mammary ductal carcinoma in situ: Clinical implications. Semin Diagn Pathol 3:193-198, 1994.
9. Noguchi S, Aihara T, Koyama H, et al.: Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 74:872-877, 1994.
10. Borger J, Kemperman H, Hart A, et al.: Risk factors in breast-conservation therapy. J Clin Oncol 12:653-660, 1994.
11. Harris JR, Gelman R: What have we learned about risk factors for local recurrence after breast-conserving surgery and irradiation? Editorial. J Clin Oncol 12: 647-649, 1994.
12. Connolly JL, Schnitt SJ: Evaluation of breast specimen in patients considered for treatment by conservative surgery and radiation therapy for early breast cancer. Path Ann 23:1-23, 1988.
13. Sloane JP: Royal College of Pathologists Working Group. Pathology reporting in breast cancer screening. J Clin Pathol 44:710-725, 1991.
14. Holland R, Peterse JL, Millis RR, et al.: Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 11:167-180, 1994.
15. Mellink WAM, Holland R, Hendriks JHCL et al.: The contribution of routine follow-up mammography to an early diagnosis of asynchronous contralateral breast cancer. Cancer 67:1844-1848, 1991.
16. Easton DF, Bishop DT, Ford D, et al.: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 52:678-701, 1993.
17. Miki Y, Swensen J, Shattuck-Eidens D, et al.: Isolation of BRCA1. The 17q-linked breast and ovarian cancer susceptibility gene. Science 266:66-71, 1994.
18. Wooster R, Neuhasen SL, Mangion Y, et al.: Localization of a breast cancer susceptibility gene BRCA2 to chromosome 13q12-13. Science 265:2088-2090, 1994.
19. Sacks NPM, Barr LC, Allan SM, Baum M: The role of axillary dissection in operable breast cancer. Breast 1:41-49, 1992.
20. Hayes DF: Axillary lymphoscintigraphy for breast cancer. Should we do it? Can we do it? J Nucl Med 31:1835-1838, 1990.
21. Tjandra J, Russell I, Colins J, et al.: Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer. Cancer Res 49:1600-1608, 1989.
22. Tate JJT, Lewis V, Archer T, et al.: Ultrasound detection of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 15:139-141, 1989.
23. Koscielny S, Le MG, Tubiana M.: The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 59:775-782, 1989.
24. Carter CL, Allen C, Henson DE: Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989.
25. Chadha M, Chabon AB, Friemann P, Vikram B: Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer 73:350-353, 1994.
26. Fentimen IS, Mansel RE: The axilla; not a no-go zone. Lancet 337:221-223, 1991.
27. Axelsson CK, Mouridsen HT, Zedeler K, on behalf of the Danish Breast Cancer Cooperative Group (DBCG): Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 28A: 1415-1418, 1992.
28. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K: Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 14:407-412, 1988.
29. Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 320:391-401, 1994.
30. Krag DN, Weaver DL, Alex JC, Fairbank JT: Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2:335-340, 1993.
31. Tubiana M, Koscielny S: Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 18:125-140, 1991.
32. Fisher ER, Costantino PH, Fisher B, Redmond C: Pathologic findings from the National Surgical Adjuvant Breast Projet (protocol 4), Discriminants for 15-year survival. Cancer (suppl)71:2141-2150, 1993.
33. Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease and histologic grade from 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68:2142-2149, 1991.
34. Contesso G, Mouriesse H, Friedman S, et al.: The importance of histologic grade in long-term prognosis of breast cancer. A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386, 1987.
35. Page DL: Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. An J Surg Pathol 15(4):334-349, 1991.
36. Hellman S: Natural history of small breast cancer. Karnofsky memorial lecture. J Clin Oncol 12:2229-2234, 1994.
37. Tabar L, Fagerberg G, Day NE, et al.: Breast cancer treatment and natural history: new insights from results of screening. Lancet 339:412-414, 1992.
38. Thompson AM, Steel CM, Chetty U, Carter DC: Evidence for the multistep theory of carcinogenesis in human breast cancer. Breast 1:29-34, 1992.
39. Henderson IC: Biologic variations of tumour. Cancer 69:1888-1895, 1992.
40. Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10:679-682, 1992.
41. Rosner D, Lane WW: Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 68:1482-1494, 1991.
42. Consensus Development Panel: Consensus statement: treatment of early stage breast cancer. In: "Consensus Development Conference on the Treatment of Early Stage Breast Cancer." J Natl Cancer Inst Monog no. 11, 1-5 NIH publication no. 90-3187. Washington DC: Government Printing Office, 1992.
43. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992.
44. Loprinzi CL, Ravdin PMM, De Laurentis M, Novotny P: Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 12:1422-1426, 1994.
45. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
46. Stewart HJ: Adjuvant ovarian ablation for primary breast cancer. Breast 3:139-140, 1994.
47. Nevill AM, Bettelheim R, Gelber RD: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin One 10:696-705, 1992.
48. O'Reilly SM, Camplejohn RS, Millis RR, et al.: Proliferative activity, bistological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 26:1035-1038, 1990.
49. Remvikos Y, Beuzeboc P, Zajdela A, et al.: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:1383-1386, 1989.
50. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992.
51. Muss HB, Thor AD, Berry DA, et al.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
52. Diest PJ van, Baak JPA: The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients. Hum Pathol 22:326-330, 1991.
53. Wall vdE, Richel DJ, Kusumanto YM, et al.: Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann Oncol 9:791-792, 1993.
54. Henderson IG: Breast cancer therapy - the price of success. N Engl J Med 326:1774-1775, 1992.
55. Gelber RD, Goldhirsch A, Coates AS: Adjuvant therapy for breast cancer: understanding the overview. J Clin Oncol 11:580-585, 1993.
56. Rutgers EJTh, Van Slooten EA, Kluck HM: Follow-up after treatment of primary breast cancer. Br J Surg 77:187-190, 1989.
57. Roselli del Turco MR, Palli D, Cariddi A, et al.: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271:1593-1597, 1994.
58. Osborne MP, Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncology 8:25-42, 1994.
59. Harbeck N, Untch M, Fach L, Eiermann W.: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69:566-571, 1994.
60. Ravdin PM, Clark GM: A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 22:285-293, 1992.
61. McGuire WL: Breast cancer prognostic factors: evaluation guidelines. (Editorial). J Natl Cancer Inst 83:154-155, 1991.